Cargando…
Integrative omics reveals MYCN as a global suppressor of cellular signalling and enables network-based therapeutic target discovery in neuroblastoma
Despite intensive study, many mysteries remain about the MYCN oncogene's functions. Here we focus on MYCN's role in neuroblastoma, the most common extracranial childhood cancer. MYCN gene amplification occurs in 20% of cases, but other recurrent somatic mutations are rare. This scarcity of...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4791225/ https://www.ncbi.nlm.nih.gov/pubmed/26673823 |
_version_ | 1782421048717737984 |
---|---|
author | Duffy, David J. Krstic, Aleksandar Halasz, Melinda Schwarzl, Thomas Fey, Dirk Iljin, Kristiina Mehta, Jai Prakash Killick, Kate Whilde, Jenny Turriziani, Benedetta Haapa-Paananen, Saija Fey, Vidal Fischer, Matthias Westermann, Frank Henrich, Kai-Oliver Bannert, Steffen Higgins, Desmond G. Kolch, Walter |
author_facet | Duffy, David J. Krstic, Aleksandar Halasz, Melinda Schwarzl, Thomas Fey, Dirk Iljin, Kristiina Mehta, Jai Prakash Killick, Kate Whilde, Jenny Turriziani, Benedetta Haapa-Paananen, Saija Fey, Vidal Fischer, Matthias Westermann, Frank Henrich, Kai-Oliver Bannert, Steffen Higgins, Desmond G. Kolch, Walter |
author_sort | Duffy, David J. |
collection | PubMed |
description | Despite intensive study, many mysteries remain about the MYCN oncogene's functions. Here we focus on MYCN's role in neuroblastoma, the most common extracranial childhood cancer. MYCN gene amplification occurs in 20% of cases, but other recurrent somatic mutations are rare. This scarcity of tractable targets has hampered efforts to develop new therapeutic options. We employed a multi-level omics approach to examine MYCN functioning and identify novel therapeutic targets for this largely un-druggable oncogene. We used systems medicine based computational network reconstruction and analysis to integrate a range of omic techniques: sequencing-based transcriptomics, genome-wide chromatin immunoprecipitation, siRNA screening and interaction proteomics, revealing that MYCN controls highly connected networks, with MYCN primarily supressing the activity of network components. MYCN's oncogenic functions are likely independent of its classical heterodimerisation partner, MAX. In particular, MYCN controls its own protein interaction network by transcriptionally regulating its binding partners. Our network-based approach identified vulnerable therapeutically targetable nodes that function as critical regulators or effectors of MYCN in neuroblastoma. These were validated by siRNA knockdown screens, functional studies and patient data. We identified β-estradiol and MAPK/ERK as having functional cross-talk with MYCN and being novel targetable vulnerabilities of MYCN-amplified neuroblastoma. These results reveal surprising differences between the functioning of endogenous, overexpressed and amplified MYCN, and rationalise how different MYCN dosages can orchestrate cell fate decisions and cancerous outcomes. Importantly, this work describes a systems-level approach to systematically uncovering network based vulnerabilities and therapeutic targets for multifactorial diseases by integrating disparate omic data types. |
format | Online Article Text |
id | pubmed-4791225 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-47912252016-03-28 Integrative omics reveals MYCN as a global suppressor of cellular signalling and enables network-based therapeutic target discovery in neuroblastoma Duffy, David J. Krstic, Aleksandar Halasz, Melinda Schwarzl, Thomas Fey, Dirk Iljin, Kristiina Mehta, Jai Prakash Killick, Kate Whilde, Jenny Turriziani, Benedetta Haapa-Paananen, Saija Fey, Vidal Fischer, Matthias Westermann, Frank Henrich, Kai-Oliver Bannert, Steffen Higgins, Desmond G. Kolch, Walter Oncotarget Priority Research Paper Despite intensive study, many mysteries remain about the MYCN oncogene's functions. Here we focus on MYCN's role in neuroblastoma, the most common extracranial childhood cancer. MYCN gene amplification occurs in 20% of cases, but other recurrent somatic mutations are rare. This scarcity of tractable targets has hampered efforts to develop new therapeutic options. We employed a multi-level omics approach to examine MYCN functioning and identify novel therapeutic targets for this largely un-druggable oncogene. We used systems medicine based computational network reconstruction and analysis to integrate a range of omic techniques: sequencing-based transcriptomics, genome-wide chromatin immunoprecipitation, siRNA screening and interaction proteomics, revealing that MYCN controls highly connected networks, with MYCN primarily supressing the activity of network components. MYCN's oncogenic functions are likely independent of its classical heterodimerisation partner, MAX. In particular, MYCN controls its own protein interaction network by transcriptionally regulating its binding partners. Our network-based approach identified vulnerable therapeutically targetable nodes that function as critical regulators or effectors of MYCN in neuroblastoma. These were validated by siRNA knockdown screens, functional studies and patient data. We identified β-estradiol and MAPK/ERK as having functional cross-talk with MYCN and being novel targetable vulnerabilities of MYCN-amplified neuroblastoma. These results reveal surprising differences between the functioning of endogenous, overexpressed and amplified MYCN, and rationalise how different MYCN dosages can orchestrate cell fate decisions and cancerous outcomes. Importantly, this work describes a systems-level approach to systematically uncovering network based vulnerabilities and therapeutic targets for multifactorial diseases by integrating disparate omic data types. Impact Journals LLC 2015-12-11 /pmc/articles/PMC4791225/ /pubmed/26673823 Text en Copyright: © 2015 Duffy et al. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Priority Research Paper Duffy, David J. Krstic, Aleksandar Halasz, Melinda Schwarzl, Thomas Fey, Dirk Iljin, Kristiina Mehta, Jai Prakash Killick, Kate Whilde, Jenny Turriziani, Benedetta Haapa-Paananen, Saija Fey, Vidal Fischer, Matthias Westermann, Frank Henrich, Kai-Oliver Bannert, Steffen Higgins, Desmond G. Kolch, Walter Integrative omics reveals MYCN as a global suppressor of cellular signalling and enables network-based therapeutic target discovery in neuroblastoma |
title | Integrative omics reveals MYCN as a global suppressor of cellular signalling and enables network-based therapeutic target discovery in neuroblastoma |
title_full | Integrative omics reveals MYCN as a global suppressor of cellular signalling and enables network-based therapeutic target discovery in neuroblastoma |
title_fullStr | Integrative omics reveals MYCN as a global suppressor of cellular signalling and enables network-based therapeutic target discovery in neuroblastoma |
title_full_unstemmed | Integrative omics reveals MYCN as a global suppressor of cellular signalling and enables network-based therapeutic target discovery in neuroblastoma |
title_short | Integrative omics reveals MYCN as a global suppressor of cellular signalling and enables network-based therapeutic target discovery in neuroblastoma |
title_sort | integrative omics reveals mycn as a global suppressor of cellular signalling and enables network-based therapeutic target discovery in neuroblastoma |
topic | Priority Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4791225/ https://www.ncbi.nlm.nih.gov/pubmed/26673823 |
work_keys_str_mv | AT duffydavidj integrativeomicsrevealsmycnasaglobalsuppressorofcellularsignallingandenablesnetworkbasedtherapeutictargetdiscoveryinneuroblastoma AT krsticaleksandar integrativeomicsrevealsmycnasaglobalsuppressorofcellularsignallingandenablesnetworkbasedtherapeutictargetdiscoveryinneuroblastoma AT halaszmelinda integrativeomicsrevealsmycnasaglobalsuppressorofcellularsignallingandenablesnetworkbasedtherapeutictargetdiscoveryinneuroblastoma AT schwarzlthomas integrativeomicsrevealsmycnasaglobalsuppressorofcellularsignallingandenablesnetworkbasedtherapeutictargetdiscoveryinneuroblastoma AT feydirk integrativeomicsrevealsmycnasaglobalsuppressorofcellularsignallingandenablesnetworkbasedtherapeutictargetdiscoveryinneuroblastoma AT iljinkristiina integrativeomicsrevealsmycnasaglobalsuppressorofcellularsignallingandenablesnetworkbasedtherapeutictargetdiscoveryinneuroblastoma AT mehtajaiprakash integrativeomicsrevealsmycnasaglobalsuppressorofcellularsignallingandenablesnetworkbasedtherapeutictargetdiscoveryinneuroblastoma AT killickkate integrativeomicsrevealsmycnasaglobalsuppressorofcellularsignallingandenablesnetworkbasedtherapeutictargetdiscoveryinneuroblastoma AT whildejenny integrativeomicsrevealsmycnasaglobalsuppressorofcellularsignallingandenablesnetworkbasedtherapeutictargetdiscoveryinneuroblastoma AT turrizianibenedetta integrativeomicsrevealsmycnasaglobalsuppressorofcellularsignallingandenablesnetworkbasedtherapeutictargetdiscoveryinneuroblastoma AT haapapaananensaija integrativeomicsrevealsmycnasaglobalsuppressorofcellularsignallingandenablesnetworkbasedtherapeutictargetdiscoveryinneuroblastoma AT feyvidal integrativeomicsrevealsmycnasaglobalsuppressorofcellularsignallingandenablesnetworkbasedtherapeutictargetdiscoveryinneuroblastoma AT fischermatthias integrativeomicsrevealsmycnasaglobalsuppressorofcellularsignallingandenablesnetworkbasedtherapeutictargetdiscoveryinneuroblastoma AT westermannfrank integrativeomicsrevealsmycnasaglobalsuppressorofcellularsignallingandenablesnetworkbasedtherapeutictargetdiscoveryinneuroblastoma AT henrichkaioliver integrativeomicsrevealsmycnasaglobalsuppressorofcellularsignallingandenablesnetworkbasedtherapeutictargetdiscoveryinneuroblastoma AT bannertsteffen integrativeomicsrevealsmycnasaglobalsuppressorofcellularsignallingandenablesnetworkbasedtherapeutictargetdiscoveryinneuroblastoma AT higginsdesmondg integrativeomicsrevealsmycnasaglobalsuppressorofcellularsignallingandenablesnetworkbasedtherapeutictargetdiscoveryinneuroblastoma AT kolchwalter integrativeomicsrevealsmycnasaglobalsuppressorofcellularsignallingandenablesnetworkbasedtherapeutictargetdiscoveryinneuroblastoma |